1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 ASN 18 IS COVALENTLY BOUND THROUGH ND2 TO NAG 78 AT C1. Fletcher, C.M. Harrison, R.A. Lachmann, P.J. Neuhaus, D. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C6 H12 O5 164.156 alpha-L-fucopyranose L-saccharide, alpha linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C8 H15 N O6 221.208 2-acetamido-2-deoxy-beta-D-glucopyranose D-saccharide, beta linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking UK Structure STRUE6 2005 0969-2126 2 185 199 10.1016/S0969-2126(00)00020-4 7520819 Structure of a soluble, glycosylated form of the human complement regulatory protein CD59. 1994 US Protein Sci. PRCIEI 0795 0961-8368 2 2015 Sequence-Specific 1H-NMR Assignments and Folding Topology of Human Cd59 1993 US Immunol.Res. 2031 0257-277X 12 258 Membrane Defence Against Complement Lysis: The Structure and Biological Properties of Cd59 1993 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 8970.106 CD59 1 man polymer 570.542 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose 1 man branched no no LQCYNCPNPTADCKTAVNCSSDFDACLITKAGLQVYNKCWKFEHCNFNDVTTRLRENELTYYCCKKDLCNFNEQLEN LQCYNCPNPTADCKTAVNCSSDFDACLITKAGLQVYNKCWKFEHCNFNDVTTRLRENELTYYCCKKDLCNFNEQLEN A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n human sample 9606 Homo sapiens atom_site chem_comp entity pdbx_branch_scheme pdbx_chem_comp_identifier pdbx_database_status pdbx_entity_branch pdbx_entity_branch_descriptor pdbx_entity_branch_link pdbx_entity_branch_list pdbx_entity_nonpoly pdbx_nonpoly_scheme pdbx_struct_assembly_gen struct_asym struct_conn struct_site struct_site_gen repository Initial release Carbohydrate remediation repository Remediation Version format compliance Non-polymer description Version format compliance Atomic model Data collection Derived calculations Other Structure summary 1 0 1994-09-30 1 1 2008-03-24 1 2 2011-07-13 2 0 2020-07-29 _atom_site.auth_asym_id _atom_site.auth_seq_id _atom_site.label_asym_id _atom_site.label_entity_id _chem_comp.name _chem_comp.type _pdbx_database_status.process_site _pdbx_struct_assembly_gen.asym_id_list _struct_conn.pdbx_leaving_atom_flag _struct_conn.pdbx_role _struct_conn.ptnr1_auth_asym_id _struct_conn.ptnr1_auth_seq_id _struct_conn.ptnr2_auth_asym_id _struct_conn.ptnr2_auth_seq_id _struct_conn.ptnr2_label_asym_id NAG 78 n B NAG 1 NAG 79 n B NAG 2 FUC 80 n B FUC 3 LFucpa a-L-fucopyranose a-L-Fucp Fuc DGlcpNAcb N-acetyl-b-D-glucopyranosamine b-D-GlcpNAc GlcNAc Y BNL 1994-06-01 REL oligosaccharide DGlcpNAcb1-4[LFucpa1-6]DGlcpNAcb1- 2 GMML 1.0 Glycam Condensed Sequence WURCS=2.0/2,3,2/[a2122h-1b_1-5_2*NCC/3=O][a1221m-1a_1-5]/1-1-2/a4-b1_a6-c1 2 PDB2Glycan 1.1.0 WURCS []{[(4+1)][b-D-GlcpNAc]{[(4+1)][b-D-GlcpNAc]{}[(6+1)][a-L-Fucp]{}}} 2 PDB-CARE LINUCS C1 O4 NAG NAG 2 1 2 O1 HO4 sing C1 O6 FUC NAG 3 1 2 O1 HO6 sing n n n 10 BRUNGER refinement X-PLOR LEU 1 n 1 LEU 1 A GLN 2 n 2 GLN 2 A CYS 3 n 3 CYS 3 A TYR 4 n 4 TYR 4 A ASN 5 n 5 ASN 5 A CYS 6 n 6 CYS 6 A PRO 7 n 7 PRO 7 A ASN 8 n 8 ASN 8 A PRO 9 n 9 PRO 9 A THR 10 n 10 THR 10 A ALA 11 n 11 ALA 11 A ASP 12 n 12 ASP 12 A CYS 13 n 13 CYS 13 A LYS 14 n 14 LYS 14 A THR 15 n 15 THR 15 A ALA 16 n 16 ALA 16 A VAL 17 n 17 VAL 17 A ASN 18 n 18 ASN 18 A CYS 19 n 19 CYS 19 A SER 20 n 20 SER 20 A SER 21 n 21 SER 21 A ASP 22 n 22 ASP 22 A PHE 23 n 23 PHE 23 A ASP 24 n 24 ASP 24 A ALA 25 n 25 ALA 25 A CYS 26 n 26 CYS 26 A LEU 27 n 27 LEU 27 A ILE 28 n 28 ILE 28 A THR 29 n 29 THR 29 A LYS 30 n 30 LYS 30 A ALA 31 n 31 ALA 31 A GLY 32 n 32 GLY 32 A LEU 33 n 33 LEU 33 A GLN 34 n 34 GLN 34 A VAL 35 n 35 VAL 35 A TYR 36 n 36 TYR 36 A ASN 37 n 37 ASN 37 A LYS 38 n 38 LYS 38 A CYS 39 n 39 CYS 39 A TRP 40 n 40 TRP 40 A LYS 41 n 41 LYS 41 A PHE 42 n 42 PHE 42 A GLU 43 n 43 GLU 43 A HIS 44 n 44 HIS 44 A CYS 45 n 45 CYS 45 A ASN 46 n 46 ASN 46 A PHE 47 n 47 PHE 47 A ASN 48 n 48 ASN 48 A ASP 49 n 49 ASP 49 A VAL 50 n 50 VAL 50 A THR 51 n 51 THR 51 A THR 52 n 52 THR 52 A ARG 53 n 53 ARG 53 A LEU 54 n 54 LEU 54 A ARG 55 n 55 ARG 55 A GLU 56 n 56 GLU 56 A ASN 57 n 57 ASN 57 A GLU 58 n 58 GLU 58 A LEU 59 n 59 LEU 59 A THR 60 n 60 THR 60 A TYR 61 n 61 TYR 61 A TYR 62 n 62 TYR 62 A CYS 63 n 63 CYS 63 A CYS 64 n 64 CYS 64 A LYS 65 n 65 LYS 65 A LYS 66 n 66 LYS 66 A ASP 67 n 67 ASP 67 A LEU 68 n 68 LEU 68 A CYS 69 n 69 CYS 69 A ASN 70 n 70 ASN 70 A PHE 71 n 71 PHE 71 A ASN 72 n 72 ASN 72 A GLU 73 n 73 GLU 73 A GLN 74 n 74 GLN 74 A LEU 75 n 75 LEU 75 A GLU 76 n 76 GLU 76 A ASN 77 n 77 ASN 77 A author_defined_assembly 1 monomeric A ASN 18 GLYCOSYLATION SITE A ASN 18 ASN 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 A N CYS 3 A N CYS 3 A O VAL 17 A O VAL 17 A O TRP 40 A O TRP 40 A N ALA 25 A N ALA 25 A O CYS 26 A O CYS 26 A N CYS 64 A N CYS 64 1 A ARG 53 0.305 SIDE CHAIN 1 A ARG 55 0.281 SIDE CHAIN 2 A ARG 53 0.245 SIDE CHAIN 2 A ARG 55 0.150 SIDE CHAIN 3 A ARG 53 0.233 SIDE CHAIN 3 A ARG 55 0.314 SIDE CHAIN 4 A ARG 53 0.215 SIDE CHAIN 4 A ARG 55 0.207 SIDE CHAIN 5 A ARG 53 0.217 SIDE CHAIN 5 A ARG 55 0.317 SIDE CHAIN 6 A ARG 53 0.295 SIDE CHAIN 6 A ARG 55 0.299 SIDE CHAIN 7 A ARG 53 0.273 SIDE CHAIN 7 A ARG 55 0.282 SIDE CHAIN 8 A ARG 53 0.115 SIDE CHAIN 8 A ARG 55 0.314 SIDE CHAIN 9 A ARG 53 0.312 SIDE CHAIN 9 A ARG 55 0.313 SIDE CHAIN 10 A ARG 53 0.175 SIDE CHAIN 10 A ARG 55 0.283 SIDE CHAIN 1 A ASP 12 -171.84 42.84 1 A LYS 14 -140.52 26.30 1 A SER 20 -51.34 -177.33 1 A ALA 31 -85.93 45.08 1 A LEU 33 165.69 -45.89 1 A PHE 47 -90.89 57.12 1 A ASN 48 178.87 -32.75 1 A GLU 56 -123.57 -157.66 1 A ASN 57 -161.73 -75.40 1 A GLU 58 -59.65 102.76 1 A ASP 67 -45.44 97.95 1 A LEU 68 79.43 70.19 1 A PHE 71 -51.43 -179.82 1 A GLU 73 -157.12 51.80 1 A GLN 74 -160.42 26.15 1 A LEU 75 -147.00 21.23 2 A CYS 6 172.25 92.34 2 A ASP 12 -166.01 34.40 2 A VAL 17 177.67 137.20 2 A CYS 19 -44.99 -75.01 2 A SER 20 64.01 157.15 2 A SER 21 79.78 52.11 2 A ASP 22 63.06 81.57 2 A ALA 31 -106.98 47.36 2 A LEU 33 -171.79 -38.36 2 A ASN 48 -178.09 -33.32 2 A ASN 57 -140.61 -58.86 2 A LEU 59 -176.55 126.80 2 A LEU 68 69.11 64.25 2 A ASN 72 65.96 63.69 2 A GLU 73 179.39 43.32 2 A GLN 74 -149.30 16.19 2 A LEU 75 -154.50 21.27 3 A ASP 12 179.00 48.71 3 A SER 20 -105.89 -156.71 3 A ASP 24 -157.07 -39.46 3 A CYS 45 -100.01 73.92 3 A ASN 48 178.56 -35.82 3 A LEU 68 67.74 63.55 3 A GLU 73 -179.76 34.51 3 A GLN 74 -117.11 -74.51 3 A GLU 76 -44.21 107.45 4 A ASP 12 -173.81 35.62 4 A ALA 16 40.89 83.97 4 A ASN 48 178.81 -34.07 4 A ASN 57 -121.82 -68.16 4 A GLU 58 -58.95 90.20 4 A LYS 65 -146.54 37.85 4 A LEU 68 72.79 69.44 4 A GLU 73 177.11 38.82 4 A GLN 74 -146.25 17.56 4 A LEU 75 -131.59 -47.63 4 A GLU 76 -47.59 170.11 5 A ASP 12 -169.84 33.81 5 A CYS 19 -103.41 -60.02 5 A SER 20 42.07 -164.98 5 A SER 21 76.45 -3.14 5 A ASP 22 162.65 37.52 5 A ALA 31 -70.25 -166.44 5 A LEU 33 -151.73 -59.43 5 A PHE 47 -86.31 44.92 5 A ASN 48 -157.80 -43.00 5 A ASN 57 -170.97 49.29 5 A GLU 58 -178.52 64.72 5 A LYS 65 -142.91 28.90 5 A GLU 73 -166.40 35.69 5 A GLN 74 -121.81 -70.66 6 A ASP 12 -172.93 40.28 6 A LYS 14 -151.79 38.28 6 A SER 20 -169.52 -153.62 6 A ASP 22 77.76 43.20 6 A ALA 31 -73.34 -163.26 6 A CYS 45 -102.78 79.12 6 A PHE 47 -89.12 40.58 6 A ASN 48 -164.16 -42.44 6 A ASN 57 -161.42 -43.15 6 A LEU 59 -177.03 -164.72 6 A TYR 61 -169.57 94.21 6 A ASP 67 -50.37 98.07 6 A LEU 68 62.65 61.42 6 A ASN 72 49.35 75.20 6 A GLU 73 172.24 42.32 7 A ASP 12 -170.02 41.09 7 A LYS 14 -153.17 40.71 7 A ALA 16 46.22 84.76 7 A CYS 19 -54.54 173.60 7 A SER 20 -86.29 -157.27 7 A ASP 24 -147.98 11.51 7 A ALA 31 -54.47 -168.79 7 A LEU 33 -163.55 39.96 7 A CYS 45 -102.64 76.03 7 A PHE 47 -92.74 48.23 7 A ASN 48 -174.34 -39.33 7 A GLU 56 -127.07 -161.95 7 A ASN 57 -152.98 -58.62 7 A ASP 67 -44.71 102.30 7 A LEU 68 67.48 65.48 7 A ASN 70 -101.10 70.56 7 A GLU 73 -177.66 62.99 7 A GLN 74 -158.81 -50.03 8 A ASP 12 -159.54 37.04 8 A LYS 14 -179.71 31.98 8 A ALA 16 41.83 95.97 8 A SER 21 165.78 -48.92 8 A ASP 22 -145.83 36.22 8 A ASP 24 -155.04 21.87 8 A ALA 25 179.75 114.43 8 A LYS 30 -151.28 89.54 8 A PHE 47 -86.25 48.64 8 A ASN 48 -164.86 -37.08 8 A GLU 56 -117.68 -157.80 8 A ASN 57 -157.69 -61.77 8 A LEU 59 177.35 134.39 8 A LYS 65 -142.27 31.33 8 A ASP 67 -49.01 103.17 8 A LEU 68 63.27 63.11 8 A PHE 71 -178.68 31.85 8 A GLU 73 -157.22 37.13 8 A GLN 74 -125.80 -55.57 8 A GLU 76 -48.01 162.31 9 A ALA 11 -98.54 35.48 9 A ASP 12 -178.69 43.59 9 A CYS 13 -47.44 175.94 9 A LYS 14 -179.92 32.23 9 A ALA 16 46.75 97.59 9 A SER 21 -173.79 54.39 9 A ALA 25 -163.65 115.38 9 A ALA 31 -57.01 173.76 9 A LEU 33 -173.43 -43.82 9 A ASN 48 -131.38 -34.59 9 A VAL 50 -122.81 -54.78 9 A GLU 56 -120.03 -167.46 9 A ASN 57 -163.95 -40.81 9 A LYS 65 -164.95 42.27 9 A ASN 72 43.92 74.57 9 A GLU 73 173.11 35.90 9 A GLN 74 -109.85 -76.56 9 A GLU 76 64.90 96.61 10 A CYS 6 175.23 105.66 10 A ASP 12 -157.09 33.78 10 A LYS 14 -146.21 42.58 10 A THR 15 -115.09 70.10 10 A ASP 22 170.27 35.32 10 A PHE 23 179.28 177.20 10 A ASP 24 -170.42 26.37 10 A ALA 25 164.21 124.26 10 A ARG 55 71.36 34.88 10 A ASN 57 -140.19 -71.67 10 A LEU 59 -173.00 101.82 10 A LYS 65 -168.49 28.64 10 A LYS 66 -98.70 30.91 10 A ASP 67 65.46 105.44 10 A PHE 71 -107.97 -168.31 10 A ASN 72 -94.49 55.78 10 A GLU 73 -168.36 37.16 model building X-PLOR refinement X-PLOR phasing X-PLOR CD59 COMPLEXED WITH GLCNAC-BETA-1,4-GLCNAC-BETA-1 (NMR, 10 STRUCTURES) STRUCTURE OF A SOLUBLE, GLYCOSYLATED FORM OF THE HUMAN COMPLEMENT REGULATORY PROTEIN CD59 1 Y N 2 N N A PHE 47 A PHE 47 HELX_P IRREGULAR H-BONDS AT C-T END A GLU 56 A GLU 56 1 H1 10 disulf 2.019 A CYS 3 A SG CYS 3 1_555 A CYS 26 A SG CYS 26 1_555 disulf 2.021 A CYS 6 A SG CYS 6 1_555 A CYS 13 A SG CYS 13 1_555 disulf 2.019 A CYS 19 A SG CYS 19 1_555 A CYS 39 A SG CYS 39 1_555 disulf 2.020 A CYS 45 A SG CYS 45 1_555 A CYS 63 A SG CYS 63 1_555 disulf 2.021 A CYS 64 A SG CYS 64 1_555 A CYS 69 A SG CYS 69 1_555 covale 1.451 one N-Glycosylation A ASN 18 A ND2 ASN 18 1_555 B NAG 1 B C1 NAG 1_555 covale 1.391 both B NAG 1 B O4 NAG 1_555 B NAG 2 B C1 NAG 1_555 covale 1.399 both B NAG 1 B O6 NAG 1_555 B FUC 3 B C1 FUC 1_555 COMPLEMENT REGULATORY PROTEIN COMPLEMENT REGULATORY PROTEIN CD59_HUMAN UNP 1 1 P13987 MGIQGGSVLFGLLLVLAVFCHSGHSLQCYNCPNPTADCKTAVNCSSDFDACLITKAGLQVYNKCWKFEHCNFNDVTTRLR ENELTYYCCKKDLCNFNEQLENGGTSLSEKTVLLLVTPFLAAAWSLHP 26 102 1CDR 1 77 P13987 A 1 1 77 2 3 anti-parallel anti-parallel anti-parallel A LEU 1 A LEU 1 A CYS 6 A CYS 6 A THR 15 A THR 15 A CYS 19 A CYS 19 A GLN 34 A GLN 34 A TRP 40 A TRP 40 A ALA 25 A ALA 25 A ALA 31 A ALA 31 A LEU 59 A LEU 59 A LYS 65 A LYS 65 1 P 1